Effect ofABCB1(MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects
Open Access
- 21 July 2006
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 63 (1) , 53-58
- https://doi.org/10.1111/j.1365-2125.2006.02733.x
Abstract
Aim: We aimed to investigate the effect of theABCB1gene on the pharmacokinetics of amlodipine.Methods: Based on polymorphisms of theABCB1gene at positions 2677 and 3435, 26 healthy male participants were divided into three groups: subjects with 2677GG/3435CC (n = 9), 2677GT/3435CT (n = 9) and 2677TT/3435TT (n = 8). After a single‐dose administration of 5 mg amlodipine, plasma concentrations of amlodipine were measured and its pharmacokinetic characteristics were compared according toABCB1genotype.Results: The area under the plasma concentration–time curve was significantly lower in subjects with 2677TT/3435TT (140.8 ± 35.6 ng h−1 ml−1) and 2677GT/3435CT (149.8 ± 40.1 ng h−1 ml−1) than in those with 2677GG/3435CC (208.6 ± 39.2 ng h−1 ml−1) [95% confidence interval (CI) on the difference, 2677GG/3435CCvs.2677GT/3435CT 12.0, 105.6,P < 0.01; 2677GG/3435CCvs.2677TT/3435TT 19.6, 116.0,P < 0.01; 2677GT/3435CTvs.2677TT/3435TT − 39.2, 57.2,P > 0.05]. The peak plasma concentrations were highest in subjects with 2677GG/3435CC (3.8 ± 0.5 ng ml−1), lower in subjects with 2677GT/3435CT (3.2 ± 0.5 ng ml−1) and 2677TT/3435TT (2.7 ± 0.5 ng ml−1) in rank and showed a significant difference between those with 2677GG/3435CC and with 2677TT/3435TT (95% CI on the difference 0.4, 2.0,P < 0.01). However, the oral clearance was higher in subjects with 2677TT/3435TT (37.7 ± 10.2 l h−1) than in those with 2677GT/3435CT (35.7 ± 9.9 l h−1) and with 2677GG/3435CC (24.8 ± 5.4 l h−1) and exhibited a significant difference betweenABCB1genotype groups (95% CI on the difference, 2677GG/3435CCvs.2677GT/3435CT − 21.5, − 0.3,P < 0.05; 2677GG/3435CCvs.2677TT/3435TT − 23.8, − 2.0,P < 0.05).Conclusion: Amlodipine pharmacokinetics was affected by the genetic polymorphisms of theABCB1gene in humans. These findings may provide a plausible explanation for interindividual variation in the disposition of amlodipine, although our study could not explain the exact mechanism(s) by which the polymorphicABCB1gene paradoxically reduces the plasma levels of amlodipine. Further evaluation is thus warranted.Keywords
This publication has 28 references indexed in Scilit:
- An Interethnic Comparison of Polymorphisms of the Genes Encoding Drug-Metabolizing Enzymes and Drug Transporters: Experience in SingaporeDrug Metabolism Reviews, 2005
- Simple and rapid HPLC method for determination of amlodipine in human serum with fluorescence detection and its use in pharmacokinetic studiesJournal of Pharmaceutical and Biomedical Analysis, 2004
- The MDR1 (ABCB1) Gene Polymorphism and its Clinical ImplicationsClinical Pharmacokinetics, 2004
- Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients1Transplantation, 2003
- Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) genePharmacogenetics, 2003
- MDR1 gene polymorphisms and disposition of the P‐glycoprotein substrate fexofenadineBritish Journal of Clinical Pharmacology, 2002
- Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteersEuropean Journal of Clinical Pharmacology, 1996
- P‐glycoprotein‐mediated transcellular transport of MDR‐reversing agentsFEBS Letters, 1993
- Clinical Pharmacokinetics of AmlodipineClinical Pharmacokinetics, 1992
- The pharmacokinetic profile of amlodipineAmerican Heart Journal, 1989